Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Shanghai 18 Guangzhou 18 Beijing 16 Changsha 9 Hangzhou 8

Trials with a site in Beijing

16 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
NCT07622706NSCLC, EGFR Positive Non-small Cell Lung Cancer, Neoadjuvant Therapy
Peking University Cancer Hospital & Institute
Phase 2
60
Beijing
2026-09-03
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
36
Beijing
2025-11-27
Not yet open
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xi’an, Hangzhou
2025-07-31
Recruiting
Peking University Cancer Hospital & Institute
Not applicable
286
Beijing
2025-04-06
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
300
Beijing
2025-03-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
4,000
Beijing
2024-03-01
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Recruiting
Peking Union Medical College
Not applicable
150
Beijing
2023-10-10
Recruiting
TYK Medicines, Inc
Phase 2
420
Beijing
2023-08-17
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Active, closed
AstraZeneca
Phase 3
1,350
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Kunming
2022-12-29
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Active, closed
Allist Pharmaceuticals, Inc.
Phase 1/2
315
Beijing
2021-07-26
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

11 of the 16 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 16 studies
PhaseStudiesRecruitingShare
Phase 25431.3%
Phase 33218.8%
Not applicable2212.5%
Phase 42012.5%
Early Phase 1116.3%
Observational116.3%
Phase 1116.3%
Phase 1/2106.3%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Allist Pharmaceuticals, Inc.21
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
Peking University Cancer Hospital & Institute22
Pfizer20
AstraZeneca10
Haisco Pharmaceutical Group Co., Ltd.11
MediLink Therapeutics (Suzhou) Co., Ltd.11
Merck Sharp & Dohme LLC11
Peking Union Medical College11
Suzhou Suncadia Biopharmaceuticals Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.